葵花药业(002737) - 002737葵花药业投资者关系管理信息20260206

Group 1: Company Overview - The company, Sunflower Pharmaceutical Group Co., Ltd., focuses on traditional Chinese medicine, chemical drugs, and health products, aiming to ensure safe medication for children and build trust among consumers [2][3] - The brand matrix includes two main brands: "Sunflower" for adults and "Little Sunflower" for children, with a combined brand value exceeding 36.5 billion yuan [3] Group 2: Core Product System - The adult medication line covers key areas such as digestive system, cardiovascular, gynecology, rheumatology, and respiratory illnesses, featuring products like liver protection tablets and mesalazine enteric-coated tablets [2][3] - The children's medication line addresses respiratory, digestive, and immune support, with key products including pediatric cough syrup and zinc supplements [2][3] Group 3: Market Challenges and Strategies - In 2025, the company experienced a significant decline in performance due to proactive channel adjustments, leading to a year-on-year sales revenue decrease [3][4] - The company is focusing on brand building and marketing, with increased sales expenses expected to enhance brand value over the long term [4] - R&D investments remain strong, with ongoing development in key areas such as pediatrics and geriatrics, despite short-term performance pressures [4] Group 4: Operational Adjustments - The company initiated inventory optimization in the second half of 2024, with the goal of restoring normal operations by the end of 2025 [4] - A multi-faceted approach to managing raw material costs has been established, including differentiated procurement strategies and supply chain optimization to mitigate risks from price fluctuations in traditional Chinese medicine materials [4][5] Group 5: Future Outlook - The company plans to enhance its presence in the health sector, leveraging the "Little Sunflower" brand to build an online and omnichannel operational system [5] - Continuous monitoring of market trends and governance improvements are in place to ensure sustainable growth and investor confidence [5]